Friday, 20 November 2026European Markets

NANOBIOTIX Stock Is 12% Up So Far Today

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

as of 11:05 est monday morning, shares of nanobiotix, a clinical-stage biotechnology firm, had witnessed five consecutive sessions of gains, which resulted in its share price rising 12.07% to eur8.45. this outperformed the cac 40 index which saw its value fall 0.19% over that same time frame. this could suggest there has been some weakness during monday trading session or could indicate potential weakness further ahead.

nanobiotix's share price performance

nanobiotix closed its previous trading day at eur7.54, just missing their 52-week high of eur7.60 by 0.79%. their primary aim is to develop solutions for cancer and other unmet medical needs; their flagship product candidate nbtxr3 being their prime example.

comparison to moving averages

nanobiotix's worth has significantly outshone both its 50-day moving average of eur5.01 and 200-day moving average of eur3.95 since march 2017, signaling a promising trend for shareholders. unfortunately, though, its trailing twelve-month earnings per share (eps) figure of eur-1.74 indicates a lack of profitability during this time.

trading volume & investor enthusiasm

nanobiotix reported an impressive last-day trading volume of 736,556, an increase of 92.87% from its average volume of 381,882. this activity may indicate increased investor enthusiasm about nanobiotix shares as evidenced by their recent performance.

future prospects & partnerships

as nanobiotix joins forces with lian oncology limited to introduce nbtxr3 across markets including greater china, south korea, singapore and thailand, its share performance will likely depend heavily on this lead product candidate's successful commercialization and advancement.

more news about nanobiotix (nano.pa).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 24 Jul 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›